Evaluating Phase II/III Efficacy & Safety Insights from an ADC in EGFR-Mutated NSCLC
12:00 pm - Monday 8th March 2027
- Reviewing combined phase II and III efficacy and safety data supporting accelerated approval of the ADC in EGFR-mutated NSCLC
- Exploring key learnings on toxicity management and therapeutic index optimisation drawn from early-phase through late-phase development of the program
- Outlining key safety parameters to take forward in late-stage trials